Floatz logo

scg142 tcr-t cells

Head and Neck Cancers

The Affiliated Hospital of Qingdao UniversityCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

141 Active assets in the Head and Neck Cancers cohort.

Asset / SponsorPhaseRating
NEPENTHE
Instituto Nacional de Cancer, Brazil
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
ImmunityBio, Inc.
Phase 3BB
LIDOCAINE
Instituto Nacional de Cancer, Brazil
Phase 3BB
Carboplatin
Rapa Therapeutics LLC
Phase 3BB
Epirubicin
Thomas Jefferson University
Phase 3BB

View all 50 →

Same molecule, other indications

scg142 tcr-t cells is also rated in:

human papillomavirus-related squamous cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
vulva cancerDormant
CC
Indicative ·
43 / 100
View asset →
vaginal cancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →